In Situ Produced 7-Chlorokynurenate Provides Protection against Quinolinate- and Malonate-Induced Neurotoxicity in the Rat Striatum

Beal, 1986, Replication of the neurochemical characteristics of Huntington's disease by quinolinic acid, Nature, 321, 168, 10.1038/321168a0 Blight, 1995, Quinolinic acid accumulation and functional deficits following experimental spinal cord injury, Brain, 118, 735, 10.1093/brain/118.3.735 Ceresoli, 1997, Metabolism of [5-3H]-kynurenine in the developing rat brain in vivo: Effect of intrastriatal ibotenate injections, Dev. Brain Res., 100, 73, 10.1016/S0165-3806(97)00029-1 Ceresoli-Borroni, 1999, Acute and chronic changes in kynurenate formation following an intrastriatal quinolinate injection in rats, J. Neural Transm., 106, 229, 10.1007/s007020050153 Coyle, 1976, Lesion of striatal neurons with kainic acid provides a model for Huntington's chorea, Nature, 263, 244, 10.1038/263244a0 Danysz, 1998, Glycine and N-methyl-d-aspartate receptors: Physiological significance and possible therapeutic applications, Pharmacol. Rev., 50, 597 Foster, 1983, On the excitotoxic properties of quinolinic acid, 2,3-piperidine dicarboxylic acids and structurally related compounds, Neuropharmacology, 22, 1331, 10.1016/0028-3908(83)90221-6 Gramsbergen, 1997, Brain-specific modulation of kynurenic acid synthesis in the rat, J. Neurochem., 69, 290, 10.1046/j.1471-4159.1997.69010290.x Greene, 1995, Characterization of the excitotoxic potential of the reversible succinate dehydrogenase inhibitor malonate, J. Neurochem., 64, 430, 10.1046/j.1471-4159.1995.64010430.x Greene, 1993, Inhibition of succinate dehydrogenase by malonic acid produces an “excitotoxic” lesion in rat striatum, J. Neurochem., 61, 1151, 10.1111/j.1471-4159.1993.tb03634.x Guidetti, 1995, Metabolism of 5-3H-kynurenine in the rat brain in vivo: Evidence for the existence of a functional kynurenine pathway, J. Neurochem., 65, 2621, 10.1046/j.1471-4159.1995.65062621.x Guidetti, 1997, Characterization of rat brain kynurenine aminotransferases I and II, J. Neurosci. Res., 50, 457, 10.1002/(SICI)1097-4547(19971101)50:3<457::AID-JNR12>3.0.CO;2-3 Hawkinson, 1997, The N-methyl-d-aspartate (NMDA) receptor glycine site antagonist ACEA 1021 does not produce pathological changes in rat brain, Brain Res., 744, 227, 10.1016/S0006-8993(96)01064-5 Hodgkins, 1998, Interference with cellular energy metabolism reduces kynurenic acid formation in rat brain slices: Reversal by lactate and pyruvate, Eur. J. Neurosci., 10, 1986, 10.1046/j.1460-9568.1998.00208.x Hodgkins, 1998, Uptake and metabolism of 4-chlorokynurenine in rat brain slices: Studies on the regulation of 7-chlorokynurenic acid synthesis, Soc. Neurosci. Abstr., 24 Hokari, 1996, Facilitated brain uptake of 4-chlorokynurenine and conversion to 7-chlorokynurenic acid, NeuroReport, 8, 15, 10.1097/00001756-199612200-00004 Kemp, 1988, 7-Chlorokynurenic acid is a selective antagonist at the glycine modulatory site of the N-methyl-d-aspartate receptor complex, Proc. Natl. Acad. Sci. USA, 85, 6547, 10.1073/pnas.85.17.6547 Kerr, 1997, Kynurenine pathway inhibition with 6-chloro-d-tryptophan reduces neurotoxicity of HIV-1-infected macrophages, Neurology, 49, 1671, 10.1212/WNL.49.6.1671 Kessler, 1989, A glycine site associated with N-methyl-d-aspartic acid receptors: Characterization and identification of a new class of antagonists, J. Neurochem., 52, 1319, 10.1111/j.1471-4159.1989.tb01881.x Kulagowski, 1994, 3′-(Arylmethyl)- and 3′-(aryloxy)-3-phenyl-4-hydroxyquinolin-2 (1H)-ones: Orally active antagonists of the glycine site on the NMDA receptor, J. Med. Chem., 37, 1402, 10.1021/jm00036a002 Leeson, 1994, The glycine site on the NMDA receptor—Activity relationships and therapeutic potential, J. Med. Chem., 37, 4053, 10.1021/jm00050a001 Lowry, 1951, Protein measurement with Folin phenol reagent, J. Biol. Chem., 193, 265, 10.1016/S0021-9258(19)52451-6 McQuaid, 1992, 3-Phenyl-4-hydroxyquinolin-2-(1H)-ones: Potent and selective antagonists at the strychnine-insensitive glycine site on the N-methyl-d-aspartate receptor complex, J. Med. Chem., 35, 3423, 10.1021/jm00096a019 Meldrum, 1991 Naritsin, 1995, Metabolism of l-tryptophan to kynurenate and quinolinate in the central nervous system: Effects of 6-chlorotryptophan and 4-chloro-3-hydroxyanthranilate, J. Neurochem., 65, 2217, 10.1046/j.1471-4159.1995.65052217.x Okuno, 1991, Two kynurenine aminotransferases in human brain, Brain Res., 542, 307, 10.1016/0006-8993(91)91583-M Olney, 1989, Pathological changes induced in cerebrocortical neurons by phencyclidine and related drugs, Science, 244, 1360, 10.1126/science.2660263 Parli, 1980, Metabolism of 6-chlorotryptophan to 4-chloro-3-hydroxyanthranilic acid: A potent inhibitor of 3-hydroxyanthranilic acid oxidase, Arch. Biochem. Biophys., 203, 161, 10.1016/0003-9861(80)90164-2 Poeggeler, 1998, Dopaminergic control of kynurenate levels and NMDA toxicity in the developing rat striatum, Dev. Neurosci., 20, 146, 10.1159/000017309 Roberts, 1992, Immunocytochemical localization of kynurenine aminotransferase in the rat striatum. A light and electron microscopic study, J. Comp. Neurol., 326, 82, 10.1002/cne.903260107 Salituro, 1994, Enzyme-activated antagonists of the strychnine-insensitive glycine/NMDA receptor, J. Med. Chem., 37, 334, 10.1021/jm00029a003 Schwarcz, 1983, Quinolinic acid: An endogenous metabolite that causes axon-sparing lesions in rat brain, Science, 219, 316, 10.1126/science.6849138 Stone, 1981, Quinolinic acid: A potent endogenous excitant at amino acid receptors in CNS, Eur. J. Pharmacol., 72, 411, 10.1016/0014-2999(81)90587-2 Todd, 1989, Preparation of 4-halo-3-hydroxyanthranilates and demonstration of their inhibition of 3-hydroxyanthranilate oxygenase in rat and human brain tissue, Prep. Biochem., 19, 155 Wu, 1997, Enzyme-catalyzed production of the neuroprotective NMDA receptor antagonist 7-chlorokynurenic acid in the rat brain in vivo, Eur. J. Pharmacol., 319, 13, 10.1016/S0014-2999(96)00829-1